Skip navigation
Skip navigation

Vedolizumab as induction and maintenance therapy for Crohn's disease

Sandborn, William J.; Feagan, Brian G.; Rutgeerts, Paul; Hanauer, Stephen; Colombel, Jean-Frédéric; Sands, Bruce E.; Lucas, Milan; Fedorak, Richard N.; Lee, Scott; Bressler, Brian; Pavli, Paul


BACKGROUND: The efficacy of vedolizumab, an α4β 7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with activ

CollectionsANU Research Publications
Date published: 2013
Type: Journal article
Source: New England Journal of Medicine
DOI: 10.1056/NEJMoa1215739


File Description SizeFormat Image
01_Sandborn_Vedolizumab_as_induction_and_2013.pdf700.22 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  20 July 2017/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator